pembrolizumab,bevacizumab
merck,roche
['key,note,42', 'keynote-826', 'pembro', ' bev ']
#asco2023
final os analysis results of keynote-826:
median follow-up was 39.1 mo.
the addition of pembro to chemo bev significantly reduced the risk of death by 40% in the pd-l1 cps 1 population, by 37% in the all-comer population, and by 42% in the cps 10 population.
Director, Global Healthcare Activities Academy, Editor in Chief, Global Journal of Medical Therapeutics, Consultant Oncology Clinical Pharmacist